Thread by @WHO

WHO & @MedsPatentPool announce the first transparent, global, non-exclusive licence for a #COVID19 technology, after finalizing a licensing agreement with @CSIC for a COVID-19 serological antibody technology.

👉 bit.ly/3nJQMtL

The test effectively checks for the presence of anti-SARS-CoV-2 antibodies developed either in response to an infection or to a vaccine. This represents the first test licence signed by @MedsPatentPool & included in WHO’s #COVID19 Technology Access Pool

👉bit.ly/3nJQMtL

The aim of the licence is to facilitate the rapid manufacture and commercialization of @CSIC’s #COVID19 serological test worldwide. The agreement covers all related patents and the biological material necessary for manufacture of the test.

👉bit.ly/3nJQMtL

The licence for the #COVID19 serological antibody technology will be royalty-free for low- & middle-income countries & will remain valid until the date the last patent expires. @CSIC will provide all know-how to @MedsPatentPool &/or to prospective licensees as well as training.

The technology has the potential to distinguish the immune response of #COVID19 infected individuals from vaccinated individuals. This should aid further research into the level and length of immunity and the efficacy of the tools at our disposal.

👉bit.ly/3nJQMtL

The #COVID19 tests are simple to use and suitable for all settings with a basic laboratory infrastructure, such as those found in rural areas in low- and middle-income countries.

https://twitter.com/WHO/status/1463123176163053584?s=20